These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 33370281)

  • 1. Clopidogrel responder status is uninfluenced by CYP2C19*2 in Danish patients with stroke.
    Rath CL; Jørgensen NR; Wienecke T
    PLoS One; 2020; 15(12):e0236260. PubMed ID: 33370281
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of clopidogrel high on-treatment reactivity with clinical outcomes and gene polymorphism in acute ischemic stroke patients: An observational study.
    Fu H; Hu P; Ma C; Peng F; He Z
    Medicine (Baltimore); 2020 Apr; 99(15):e19472. PubMed ID: 32282698
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Associations of CYP3A4, NR1I2, CYP2C19 and P2RY12 polymorphisms with clopidogrel resistance in Chinese patients with ischemic stroke.
    Liu R; Zhou ZY; Chen YB; Li JL; Yu WB; Chen XM; Zhao M; Zhao YQ; Cai YF; Jin J; Huang M
    Acta Pharmacol Sin; 2016 Jul; 37(7):882-8. PubMed ID: 27133299
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of Genetic Polymorphisms on Clopidogrel Response and Clinical Outcomes in Patients with Acute Ischemic Stroke CYP2C19 Genotype on Clopidogrel Response.
    Han Y; Lv HH; Liu X; Dong Q; Yang XL; Li SX; Wu S; Jiang JM; Luo Z; Zhu DS; Zhang Y; Zheng Y; Guan YT; Xu JF
    CNS Neurosci Ther; 2015 Sep; 21(9):692-7. PubMed ID: 26177117
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High On-Treatment Platelet Reactivity as Predictor of Long-term Clinical Outcomes in Stroke Patients with Antiplatelet Agents.
    Lv H; Yang Z; Wu H; Liu M; Mao X; Liu X; Ding H; Shi Z; Zhou Y; Liu Q; Zhang Y; Zhou Y; Chen K; Li Z; Dong Q; Ma J; Han Y
    Transl Stroke Res; 2022 Jun; 13(3):391-398. PubMed ID: 34596891
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The CYP2C19*2 and CYP2C19*17 Polymorphisms play a Vital Role in Clopidogrel Responsiveness after Percutaneous Coronary Intervention: A Pharmacogenomics Study.
    Saydam F; Değirmenci İ; Birdane A; Özdemir M; Ulus T; Özbayer C; Çolak E; Ata N; Güneş HV
    Basic Clin Pharmacol Toxicol; 2017 Jul; 121(1):29-36. PubMed ID: 28135763
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association with CYP2C19 polymorphisms and Clopidogrel in treatment of elderly stroke patients.
    Li C; Jia W; Li J; Li F; Ma J; Zhou L
    BMC Neurol; 2021 Mar; 21(1):104. PubMed ID: 33685396
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A study of microRNA-223 in evaluating platelet reactivity in patients with acute ischemic stroke.
    Wang DL; Li X; Wang RN; Sun Y; Xia XS; Tian WJ; Wang L
    J Physiol Pharmacol; 2022 Feb; 73(1):. PubMed ID: 35793763
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Relationship between clopidogrel resistance and genetic variability in Kawasaki disease children with coronary artery lesions].
    Cao YY; Pan QY; Li J; Zhong XF; Liang XC; He L; Chu C; Zhao QM; Zhao L; Wang F; Sun SN; Lin YX; Huang GY; Liu F
    Zhonghua Er Ke Za Zhi; 2024 Oct; 62(10):981-988. PubMed ID: 39327966
    [No Abstract]   [Full Text] [Related]  

  • 10. Antiplatelet effect of ticagrelor with aspirin in acute minor stroke and transient ischemic attack stratified by
    Zhou M; Chen W; Pan Y; Lin Y; Meng X; Zhao X; Liu L; Lin J; Li H; Wang Y; Wang Y
    Aging (Albany NY); 2020 Dec; 13(3):3994-4006. PubMed ID: 33411687
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CRISPLD1 rs12115090 polymorphisms alters antiplatelet potency of clopidogrel in coronary artery disease patients in Chinese Han.
    Wang JY; Zhang YJ; Li H; Hu XL; Li MP; Song PY; Ma QL; Peng LM; Chen XP
    Gene; 2018 Dec; 678():226-232. PubMed ID: 30096456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of high-dose clopidogrel according to CYP2C19*2 genotype in patients undergoing percutaneous coronary intervention- a systematic review and meta-analysis.
    Zhang L; Yang J; Zhu X; Wang X; Peng L; Li X; Cheng P; Yin T
    Thromb Res; 2015 Mar; 135(3):449-58. PubMed ID: 25511576
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influences of an NR1I2 polymorphism on heterogeneous antiplatelet reactivity responses to clopidogrel and clinical outcomes in acute ischemic stroke patients.
    Chen YB; Zhou ZY; Li GM; Xiao CX; Yu WB; Zhong SL; Cai YF; Jin J; Huang M
    Acta Pharmacol Sin; 2019 Jun; 40(6):762-768. PubMed ID: 30487649
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Body weight, CYP2C19, and P2Y12 receptor polymorphisms relate to clopidogrel resistance in a cohort of Chinese ischemic stroke patients with aspirin intolerance.
    Li Z; Dong W; Yang D; Sun L; He X; Hu H; Zhang J; Wang C; Li Y; Zhao M; Kong Y; Wang Y
    Eur J Clin Pharmacol; 2020 Nov; 76(11):1517-1527. PubMed ID: 32632713
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CYP2C19 polymorphisms and clopidogrel efficacy in the secondary prevention of ischemic stroke: a retrospective observational study.
    Lin J; Mo Y; Cai D; Mao D; Fu H; Wei D
    Ann Palliat Med; 2021 Dec; 10(12):12171-12180. PubMed ID: 35016407
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genotype Frequencies of CYP2C19, P2Y12 and GPIIIa Polymorphisms in Coronary Heart Disease Patients of Han Ethnicity, and Their Impact on Clopidogrel Responsiveness.
    Ou W; He Y; Li A; Liu B; Jin L
    Int Heart J; 2016 Sep; 57(5):586-92. PubMed ID: 27488401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Secondary Stroke Prophylaxis with Clopidogrel Produces Sufficient Antiplatelet Response.
    Rath CL; Jørgensen NR; Wienecke T
    J Stroke Cerebrovasc Dis; 2018 Oct; 27(10):2683-2690. PubMed ID: 29945766
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of Clopidogrel for Prevention of Stroke Based on
    Meschia JF; Walton RL; Farrugia LP; Ross OA; Elm JJ; Farrant M; Meurer WJ; Lindblad AS; Barsan W; Ching M; Gentile N; Ross M; Nahab F; Easton JD; Kim AS; Zurita KG; Cucchiara B; Johnston SC
    Stroke; 2020 Jul; 51(7):2058-2065. PubMed ID: 32568642
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10 + 12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients.
    Giusti B; Gori AM; Marcucci R; Saracini C; Sestini I; Paniccia R; Valente S; Antoniucci D; Abbate R; Gensini GF
    Pharmacogenet Genomics; 2007 Dec; 17(12):1057-64. PubMed ID: 18004210
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of gene polymorphism and high on-treatment platelet reactivity on clinical follow-up: outcomes in patients with acute coronary syndrome after drug-eluting stent implantation.
    Liang ZY; Han YL; Zhang XL; Li Y; Yan CH; Kang J
    EuroIntervention; 2013 Jul; 9(3):316-27. PubMed ID: 23872648
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.